Official Discusses Wash U's Successful Strategy in Developing a Reimbursable NGS Cancer Test | GenomeWeb

NEW YORK (GenomeWeb) – Academic institutions and molecular diagnostic companies are increasingly developing tests that run on next-generation sequencing platforms, but reimbursement for such tests can often seem arbitrary — varying depending on the specific insurer, by the test developer, the indication for the test, and even on an individual case-by-case basis.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.